Oral Administration of Specific Bioactive Collagen Peptides in the Treatment of Moderate Forms of Atopic Dermatitis: A New Approach

Proksch E, Schunck M, Zdzieblik D, Oesser S · Skin Pharmacology and Physiology

Included because it is the first collagen-peptide trial with a hard drug-sparing endpoint rather than a cosmetic one: topical corticosteroid rescue use was 0.94 g against 5.60 g on placebo (p=0.045, d=0.85), with earlier itch relief on the 5-D Pruritus Scale at week 4 and better hydration of lesional skin.

Population

Adults with moderate atopic dermatitis

Intervention

5 g specific bioactive collagen peptides (CURADERM) daily for 12 weeks

Comparator

Placebo

Limitations

Group size is not reported in the abstract and the effect sizes are implausibly large for a nutritional intervention, which usually signals a small sample. Skin barrier rather than joint. Oesser is at the Collagen Research Institute and a co-inventor on collagen-peptide patents; the product is a fourth distinct branded preparation, not VERISOL.